BioRelix Secures $3,644,085 New Funding

  • Feed Type
  • Date
    9/6/2011
  • Company Name
    BioRelix
  • Mailing Address
    5 Science Park 401 Winchester Avenue New Haven, CT 06511-1989
  • Company Description
    BioRelix, Inc. is a market-driven company that discovers and develops antibiotics that target pathogens resistant to currently available drugs. BioRelix’ competitive advantage resides in the use of novel patented bacterial RNA targets called RiboSwitches that were identified by the laboratory of BioRelix’ founder, Dr. Ronald Breaker at Yale University.
  • Website
    http://www.biorelix.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $3,644,085
  • Transaction Round
    Undisclosed
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy